EP2038653A4 - Substrates and inhibitors of antiplasmin cleaving enzyme and methods of use - Google Patents
Substrates and inhibitors of antiplasmin cleaving enzyme and methods of useInfo
- Publication number
- EP2038653A4 EP2038653A4 EP07809392A EP07809392A EP2038653A4 EP 2038653 A4 EP2038653 A4 EP 2038653A4 EP 07809392 A EP07809392 A EP 07809392A EP 07809392 A EP07809392 A EP 07809392A EP 2038653 A4 EP2038653 A4 EP 2038653A4
- Authority
- EP
- European Patent Office
- Prior art keywords
- inhibitors
- substrates
- methods
- cleaving enzyme
- antiplasmin cleaving
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/536—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase
- G01N33/542—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase with steric inhibition or signal modification, e.g. fluorescent quenching
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/001—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/02—Linear peptides containing at least one abnormal peptide link
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
- C12Q1/37—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase involving peptidase or proteinase
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/86—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood coagulating time or factors, or their receptors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Urology & Nephrology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Analytical Chemistry (AREA)
- Diabetes (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Cell Biology (AREA)
- Epidemiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- General Engineering & Computer Science (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US81156806P | 2006-06-07 | 2006-06-07 | |
US83636506P | 2006-08-08 | 2006-08-08 | |
PCT/US2007/013480 WO2007146104A2 (en) | 2006-06-07 | 2007-06-06 | Substrates and inhibitors of antiplasmin cleaving enzyme and methods of use |
Publications (2)
Publication Number | Publication Date |
---|---|
EP2038653A2 EP2038653A2 (en) | 2009-03-25 |
EP2038653A4 true EP2038653A4 (en) | 2010-04-21 |
Family
ID=38832396
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP07809392A Withdrawn EP2038653A4 (en) | 2006-06-07 | 2007-06-06 | Substrates and inhibitors of antiplasmin cleaving enzyme and methods of use |
Country Status (6)
Country | Link |
---|---|
EP (1) | EP2038653A4 (en) |
JP (1) | JP2009539853A (en) |
AU (1) | AU2007258495A1 (en) |
CA (1) | CA2658331A1 (en) |
MX (1) | MX2008015649A (en) |
WO (1) | WO2007146104A2 (en) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8933201B2 (en) | 2006-06-07 | 2015-01-13 | The Board Of Regents Of The University Of Oklahoma | Substrates and inhibitors of antiplasmin cleaving enzyme and fibroblast activation protein and methods of use |
ES2972577T3 (en) | 2016-12-14 | 2024-06-13 | Purdue Research Foundation | Imaging and therapy targeting fibroblast activation protein (FAP) |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2004072240A2 (en) * | 2003-02-07 | 2004-08-26 | Mckee Patrick A | Antiplasmin cleaving enzyme |
-
2007
- 2007-06-06 EP EP07809392A patent/EP2038653A4/en not_active Withdrawn
- 2007-06-06 WO PCT/US2007/013480 patent/WO2007146104A2/en active Application Filing
- 2007-06-06 JP JP2009514389A patent/JP2009539853A/en not_active Withdrawn
- 2007-06-06 CA CA002658331A patent/CA2658331A1/en not_active Abandoned
- 2007-06-06 MX MX2008015649A patent/MX2008015649A/en not_active Application Discontinuation
- 2007-06-06 AU AU2007258495A patent/AU2007258495A1/en not_active Abandoned
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2004072240A2 (en) * | 2003-02-07 | 2004-08-26 | Mckee Patrick A | Antiplasmin cleaving enzyme |
Non-Patent Citations (5)
Title |
---|
JACKSON ET AL.: "Determination of antiplasmin cleaving enzyme substrate specificity and inhibitor development by peptide library analyzes", FASEB JOURNAL; EXPERIMENTAL BIOLOGY 2005 MEETING/35TH INTERNATIONAL CONGRESS OF PHYSIOLOGICAL SCIENCES, FED. OF AMERICAN SOC. FOR EXPERIMENTAL BIOLOGY, BETHESDA, MD, US; SAN DIEGO, CA, USA, vol. 19, no. 4, Suppl. S, Part 1, 4 March 2006 (2006-03-04), pages A864, XP008095875, ISSN: 0892-6638 * |
LEE KYUNG N ET AL: "Antiplasmin-cleaving enzyme is a soluble form of fibroblast activation protein", BLOOD, AMERICAN SOCIETY OF HEMATOLOGY, US, vol. 107, no. 4, 1 February 2006 (2006-02-01), pages 1397 - 1404, XP002394322, ISSN: 0006-4971 * |
LEE KYUNG N ET AL: "Using substrate specificity of antiplasmin-cleaving enzyme for fibroblast activation protein inhibitor design.", BIOCHEMISTRY 16 JUN 2009, vol. 48, no. 23, 16 June 2009 (2009-06-16), pages 5149 - 5158, XP002548109, ISSN: 1520-4995 * |
OLESEN K ET AL: "Extended Subsite Characterization of Carboxypeptidase Y Using Substrates Based on Intramolecularly Quenched Fluorescence", PROTEIN AND PEPTIDE LETTERS, BENTHAM SCIENCE PUBLISHERS, SCHIPHOL, NL, vol. 3, no. 2, 1 January 1996 (1996-01-01), pages 67 - 74, XP009123391, ISSN: 0929-8665 * |
RAMANUJAM P ET AL: "Novel peptides that inhibit the propagation of Newcastle disease virus.", ARCHIVES OF VIROLOGY MAY 2002, vol. 147, no. 5, May 2002 (2002-05-01), pages 981 - 993, XP009123371, ISSN: 0304-8608 * |
Also Published As
Publication number | Publication date |
---|---|
JP2009539853A (en) | 2009-11-19 |
CA2658331A1 (en) | 2007-12-21 |
AU2007258495A1 (en) | 2007-12-21 |
MX2008015649A (en) | 2009-03-25 |
EP2038653A2 (en) | 2009-03-25 |
WO2007146104A3 (en) | 2008-10-16 |
WO2007146104A2 (en) | 2007-12-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL232786A0 (en) | Inhibitors of e1 activating enzyme | |
ME02012B (en) | Inhibitors of e1 activating enzymes | |
AP2812A (en) | Modified dicamba monooxygenase enzyme and methods of its use | |
EP2019679A4 (en) | Glucose transport inhibitors and methods of use | |
GB0619753D0 (en) | Enzyme inhibitors | |
TWI372796B (en) | Sapphire substrates and methods of making same | |
TWI350784B (en) | Sapphire substrates and methods of making same | |
IL197684A0 (en) | Stem cell culture medium and methods of use thereof | |
IL194339A0 (en) | Enzyme inhibitors | |
EP1931205A4 (en) | Transglutaminase inhibitors and methods of use thereof | |
EP2029762A4 (en) | Enzyme compositions for the improved enzymatic hydrolysis of cellulose and methods of using same | |
HK1129298A1 (en) | Dihydrodiazepines useful as inhibitors of protein kinases | |
AU2007218334A8 (en) | Methods of treating diseases using inhibitors of nucleoside phosphorylases and nucleosidases | |
IL194699A0 (en) | Tetrahydropteridines useful as inhibitors of protein kinases | |
EP2086999A4 (en) | Inhibitors for disrupting the interaction of ubiquitination related enzymes and uses thereof | |
ZA200806871B (en) | Dihydrodiazepines useful as inhibitors of protein kinases | |
EP2087339A4 (en) | Deposit removal probe and method of use | |
IL181819A0 (en) | Enzyme inhibitors and uses thereof | |
EP1915443A4 (en) | Immobilized enzymes and methods of using thereof | |
IL186120A0 (en) | Inhibitors of neurotrypsin and determination thereof | |
GB0608844D0 (en) | Enzyme inhibitors | |
GB0617161D0 (en) | Enzyme inhibitors | |
EP2038653A4 (en) | Substrates and inhibitors of antiplasmin cleaving enzyme and methods of use | |
EP2067859A4 (en) | Use of activated cytokinin-biosynthesizing enzyme gene | |
ZA200805723B (en) | Enzyme and photobleach containing compositions |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20090107 |
|
AK | Designated contracting states |
Kind code of ref document: A2 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC MT NL PL PT RO SE SI SK TR |
|
AX | Request for extension of the european patent |
Extension state: AL BA HR MK RS |
|
DAX | Request for extension of the european patent (deleted) | ||
A4 | Supplementary search report drawn up and despatched |
Effective date: 20100323 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
18D | Application deemed to be withdrawn |
Effective date: 20100622 |